Gastric Breast Cancer Network Center

Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

HOME	ABOUT US	EDITORIAL BOARD	CURRENT ISSUE	PAST ISSUES	CALL FOR PAPERS

WELCOME to		GBC e - journal		Editor-in-Chief, D. Roukos, MD, PhD		WEB
LAST UPDATE: January 22 , 2013		GBCNC Web Site		Associate Editor, J Ajani, MD Anderson, Houston, Texas		FOCUS

2010

GBC fully indexed in Scopus

SJR H Index : 2

SUBMIT YOUR PAPER

GBC

E JOURNAL

SERVICES

ARCHIVE

DOIs

NEW USER

NLM/NIH is a new subscriber to GBC

INDIVIDUALS

INSTITUTIONS/ LIBRARIES

SUBMIT A MANUSCRIPT

REVIEWERS

Links

Nature group, NEJM, JNCI, JCO

Calendar

GBC	ON LINE FIRST: 15 JANUARY 2013
	EDITORIAL
	Statins for reducing cancer death risk? Molecular evidence vs. statistics A study published recently in NEJM, which was based on the network of national databases in Denmark, reveals an antitumor effect of statins in preventing cancer. Is that true?
	NEWS & VIEWS
	Advances in gastric cancer: laparoscopic total gastrectomy, trastuzumab-emtansine and integrated genomic analysis.
GBC	CURRENT ISSUE: 2012, (Oct)Vol. 11, Issue 4, pages 196-241
	PERSPECTIVE
	Innovative drug targets: Cooperative DNA, RNA and proteins networks. High-throughput sequencing and arrays platforms provide now a global clinical genomic landscape. Computational predictive models can provide molecular networks-based identification of drug targets and prediction of therapeutic response by using signaling pathways network, PPI and gene-gene interactions analysis.
	Improving survival with trastuzumab emtansine for HER2-positive breast cancer. In patients with HER2-posutive breast cancer subtype, trastuzumab emtansine (T-DM1) as compared with lapatinib plus capecitabine in a phase 3 randomized trial, has improved survival. Can T-DM1 become a new standard treatment?
	Trametinib plus dabrafenib : Targeting RAS-MAPK pathway for BRAF V600-mutant melanoma.
	EDITORIAL
	Adding Fulvestrant to Anastrozole prolongs survival in Breast Cancer.
	Personalized medicine through genome science and network biology advances.
	Cellular signaling networks exploration for clinical applications. Understanding and predicting signaling pathways is a top research priority by pharmaceutical industry and academia. However, much more work is needed to establish robust predictive dynamics of networks.
	Healthy longevity: Approaching life mystery in genome science era. Despite advances, the achievement of healthy longevity remains an unresolved problem. In the era of genome science, network biology and clinical genome, what are the challenges to be overcome?
	NEWS & VIEWS
	Tyrosine kinase inhibitors expand indications for surgical resection of advanced GIST.
	Cancer Biomarkers: Pitfalls with traditional research and novel integrated genome analysis opportunities.
	Advances and limitations with multimodal treatment of Colorectal cancer liver metastases.
GBC	PAST ISSUE
	PERSPECTIVE
	Novel breast cancer subtypes with integrative genomic and transcriptome analysis.
	Cancer single pathways inhibitors: More resistance than durable success in the clinic
	Resistance to everolimus treatment of renal cancer, intratumor heterogeneity and new therapeutic approaches.
	EDITORIAL
	Tumor diversity: Implementing NGS into clinic
	100 breast cancer genome sequencing: Heterogeneity-based diagnostic and therapeutic perspectives.
	Overcoming resistance to cetuximab or panitumumab in KRAS wild-type colorectal cancer.
	Triple-negative breast cancer: From microarrays basal-like subtype to NGS molecular classification and new drugs development.
	NEWS & VIEWS
	Robots and surgeons: Do patients benefit? Neoadjuvant treatment and laparoscopic rectal cancer: Precision genomic medicine essential for improving patient's outcomes. Gastric cancer perspectives: Laparoscopic surgery and systems approach polypharmacology. Breast cancer advances in clinical cancer genome era: from conventional to integrative genome analysis. Vemurafenib plus cetuximab or gefitinib for BRAF(V600E) mutant colorectal cancer. Preoperative chemoradiotherapy for rectal cancer: Why revision and concerns are now shaped? Total mesorectal excision for rectal cancer: Laparoscopic or robotic approach? Dual inhibition of HER2 for a safe increase of efficacy in breast cancer. Everolimus added to aromatase inhibitors for improving hormone-receptor-positive breast cancer outcomes.
	REVIEW
	Predictive molecular tools to personalized gastric cancer targeted therapy.
	The emerging role of miRNAs in translational cancer medicine.